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Human herpesvirus 8 (HHV-8) antibodies were detect-
ed in 1 of 33 patients with pulmonary hypertension (includ-
ing in 1 of 16 with idiopathic pulmonary arterial
hypertension), 5 of 29 with cystic fibrosis, and 3 of 13 with
interstitial lung disease. No relationship between HHV-8
infection and pulmonary hypertension was found.
H
uman herpesvirus 8 (HHV-8) has been detected in
patients with Kaposi sarcoma, primary-effusion B-cell
lymphomas, and Castleman disease (1). Recently, 2 articles
from 1 group suggested that HHV-8 has a role in the patho-
genesis of idiopathic pulmonary arterial hypertension
(IPAH) (2,3). IPAH has been reported in 2 patients with
HHV-8–associated Castleman disease; lung tissue from 1
of these patients was positive for latency-associated nuclear
antigen-1 (3). HHV-8 latency-associated nuclear antigen-1
and HHV-8 viral cyclin gene were identified in the lung tis-
sue of 10 (62.5%) of 16 patients with IPAH, whereas only
1 (7.1%) of 14 patients with associated pulmonary hyper-
tension (PH) had HHV-8 gene sequences in lung tissue (2).
Conversely, Japanese researchers failed to confirm the
detection of HHV-8 latency-associated nuclear antigen-1 in
10 IPAH patients (4). 
Identifying HHV-8 as a cofactor in IPAH pathogenesis
could raise relevant therapeutic and preventive issues. We
conducted a seroprevalence study aimed at detecting anti-
bodies to HHV-8 among lung transplantation candidates;
we assessed the HHV-8 seroprevalence among PH patients
with and without IPAH, and we compared results with
those of non-PH patients. 
The Study 
We retrospectively analyzed data from 75 patients
referred to the Department of Cardiovascular and
Respiratory Sciences of the University of Rome La
Sapienza from January 2001 to February 2004 for clinical
and serologic (hepatitis C virus, hepatitis B virus, HHV-8,
and cytomegalovirus) evaluation for lung transplantation.
The diagnosis of PH was based on international criteria
(5,6). Echocardiographic data, including the right ventric-
ular end-diastolic diameter (RVEDD), were available for
all patients. Informed consent for medical and surgical
procedures was obtained for all enrolled patients.
Thirty-three of 75 patients had significant PH (mean
pulmonary arterial pressure [PAP] >25 mm Hg assessed by
right heart catheterization). Sixteen of them had IPAH
(PAP 53.4 ± 17.1 mm Hg), whereas among the 17 patients
with secondary PH, 7 patients had chronic thrombo-
embolic PH (PAP 40.3 ± 7.8), and the remaining 10
patients (PAP 37.1 ± 12.2 mm Hg) had PH associated with
connective tissue disease (4 patients), HIV infection (3
patients), and lung disease (3 patients). The 42 patients
without PH included 29 patients with cystic fibrosis (PAP
21.1 + 3.3 mm Hg) and 13 patients with interstitial lung
disease (PAP 18 ± 4.6 mm Hg) (8 patients with idiopathic
pulmonary fibrosis, 2 with sarcoidosis, 3 with pulmonary
fibrosis secondary to bleomycin treatment). 
We performed assays for antibodies directed to lytic
antigens of HHV-8 in plasma samples, according to a pre-
viously well-described method (7). Briefly, we used an in-
house indirect immune fluorescent assay based on
BCBL-1 cell line. Samples reactive at 1:40 dilution in the
antilytic test were considered positive. As assessed in a
large-scale multicenter study that employed a consensus-
based method for defining the “true” status of specimens,
this assay had the highest sensitivity of the assays evaluat-
ed (97.1%) and a specificity of 83.2% (8).
Conclusions
The 75 patients (38 male), who were candidates for
lung transplantation, were all born and living in Italy. Their
mean age was 40.5 years (range 14–74). Antibodies
against lytic antigens of HHV-8 were detected in 9 (12.0%)
patients (median HHV-8 antibody titer 1:160, range
1:80–1:320). 
No significant differences in age, sex, current residen-
cy, and cardiopulmonary symptoms (e.g., dyspnea, orthop-
nea, peripheral edema) were found between patients with
or without HHV-8 antibodies. Nevertheless, patients with
HHV-8 antibodies were generally younger (36.1 years ±
13.0 vs. 41.0 ± 14.3 years, p = 0.3) and more likely to be
male (6 [66.7%] of 9 vs. 35 [50.7%] of 69, p = 0.4 ) than
patients with no HHV-8 infection. All 3 patients with HIV
infection were HHV-8 negative. 
A higher heart rate and lower RVEDD, evaluated by
echocardiography, were found in HHV-8–seropositive
patients compared to HIV–seronegative patients (112 ± 20
vs. 89 ± 15 beats/min, p<0.001 and 22.8 ± 4.5 mm vs. 30.9
± 6.9 mm, p = 0.02, by analysis of variance). No further
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between patients with or without HHV-8 antibodies. 
A difference in the HHV-8 seroprevalence was found
between the PH patients (3.0%) and the patients without
PH (19.0%). Patients with PH were older (47.3 years ±
12.3 vs. 33.9 ± 12.7 years, p<0.001) and more like to be
male (9 [27.3%] of 33 and 30 [71.4%] of 42, p<0.001).
Among the 33 patients with PH, 1 (6.3%) of 16 with IPAH
had serologic HHV-8 antibodies, whereas no patient with
secondary PH had HHV-8 antibodies (Table). 
Among the 42 patients with no clinical or diagnostic
evidence of PH, 5 (17.2%) of the 29 with cystic fibrosis
and 3 (23.1%) of the 13 with interstitial lung disease had
HHV-8 antibodies, all of them affected by idiopathic pul-
monary fibrosis. No difference in HHV-8 seroprevalence
rate was found in patients with cystic fibrosis and in
patients with interstitial lung disease (Table). 
We found an 11.5% prevalence of HHV-8 antibodies
and a 1:160 median HHV-8 antibody titer among a popu-
lation of Italian patients who were candidates for lung
transplantation. The seroprevalence and the range of the
median end point dilution are similar to those found in the
Italian general population of blood donors, <1:40–1:160.
(8,9).
Our findings are different from those found by 1 group
of researchers (2,3) among IPAH patients and consistent
with other results (4,10). HHV-8 antibodies were detected
more frequently among young boys and patients without
PH. IPAH patients had a low HHV-8 seroprevalence rate
(6.3%) with a female prevalence (87.5%). The HHV-8
prevalence rate in Europe and the United States is higher
in men who have sex with men than in the general popula-
tion (11), whereas consistent with our results, the specific
literature on PH shows a female predominance in IPAH
patients (1.7 female/male ratio) (6). 
The higher heart rate observed in patients with HHV-8
antibodies is likely due to the higher prevalence of patients
with cystic fibrosis in this subgroup (69%). Conversely,
the higher RVEDD observed in patients without HHV-8
antibodies is likely related to the higher prevalence of dis-
eases, such as IPAH and chronic thromboembolic PH, that
cause severe right ventricular dysfunction in these patients.
The limited sample size of the population does not allow
an appropriate relevant analysis, but similar findings were
found in a previous study (12) and could be related to an
hyperdynamic circulation due to chronic infection. 
Several limitations of our study should be mentioned.
First, the high prevalence of HHV-8 antibodies among
non-PH lung transplantation candidates could be the result
of these patients’ pulmonary disease and of their previous
exposures to medical and surgical procedures not investi-
gated in this study. Indeed, as previously reported (13),
HHV-8 DNA was detected with significantly higher fre-
quency in lung tissue samples of patients affected by idio-
pathic pulmonary fibrosis. Second, we separated IPAH
from PH in the setting of autoimmune disease. We recog-
nize that distinguishing IPAH from secondary PH is not
always possible because underlying autoimmune disease
can go undiagnosed. Additionally, the pulmonary and sys-
temic pathologic features of the lung diseases being com-
pared differ, even if the result is IPAH. This observation
may affect some of the clinical physiologic parameters
reported. In conclusion, demographic and virologic issues
did not provide evidence of a direct relationship between
HHV-8 infection and PH, either idiopathic or secondary. 
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